PCI Pharma Services

PCI Pharma Services is a contract development and manufacturing organization (CDMO) that describes itself as digitally transformative. It provides solutions across the product lifecycle, from early-stage development through commercialization and beyond, supporting pharmaceutical and biopharmaceutical clients. The company reports over 8,000 people across 38 global GMP facilities in North America, Europe, and APAC. Its service areas include sterile and non-sterile development and manufacturing, clinical trial services, advanced drug delivery and drug-device combination products, and commercial packaging technology.

PCI Pharma Services presents itself as a global CDMO that supports pharmaceutical and biopharmaceutical clients from development through commercialization and beyond. The company states it has over 8,000 people in 38 global GMP facilities across North America, Europe, and APAC. It describes itself as a digitally transformative CDMO and emphasizes quality, regulatory compliance, and partnership. Its service offerings include sterile and non-sterile development and manufacturing, clinical trial services, advanced drug delivery and drug-device combination products, and commercial packaging technology. In the area of drug-device combination products, PCI provides final assembly, packaging, and testing for prefilled syringes, pens, autoinjectors, on-body injectors, and safety syringes. It also reports over 52 million FDA-approved devices assembled and over 25 years of expertise in sterile fill-finish and lyophilization.

Digitally transformative CDMO delivering life-changing therapies through quality, innovation, and partnership.

• Drug-Device Combination Products

  Comprehensive drug–device combination product services, including final assembly, packaging, and testing for prefilled syringes, pens, autoinjectors, on-body injectors, and safety syringes, with precision labelling.

• Advanced Drug Delivery & Drug-Device Combination Products

  Innovative, advanced drug-delivery solutions enabling targeted, controlled release and precise, patient-centric dosing, from clinical development to commercial scale.

• Sterile fill-finish & lyophilization

  Global manufacturing capabilities for complex sterile formulations and lyophilization, supporting next-generation injectable technologies across clinical and commercial programs, with over 25 years of expertise.

• 2021-12-14

  PCI Pharma Services completes acquisition of LSNE[5]PCI Pharma Services完成对LSNE的收购financialpost.com

  Reported: 2021-12-14

  PCI Pharma Services announced that it had closed its acquisition of Lyophilization Services of New England, Inc. (LSNE).

• 2020-02-11

  PCI Pharma Services announces acquisition of Bellwyck Pharma Services[6]PCI Pharma Services宣布收购Bellwyck Pharma Servicesfinanznachrichten.de

  Reported: 2020-02-11

  PCI Pharma Services announced its acquisition of Bellwyck Pharma Services. The acquisition is described as adding four GMP-compliant facilities to PCI’s network in the U.S., Germany and Canada.

1. 1Global CDMO. Inspired by tomorrow / PCI / Lets talk future | PCIpci.com
2. 2Global CDMO Company / PCI / Let's talk future | PCIpci.com
3. 3Drug Device Products Sterile / PCI / Let's talk future | PCIpci.com
4. 4Advanced Drug Product Packaging / PCI / Let's talk future | PCIpci.com
5. 5PCI Pharma Services完成对LSNE的收购financialpost.com
6. 6PCI Pharma Services宣布收购Bellwyck Pharma Servicesfinanznachrichten.de